Giant cell myocarditis is a rare, rapidly progressing disease that can present as acute heart failure requiring advanced therapies like LVAD and transplantation, though outcomes can still be fatal.
GCM carries high post-transplant mortality despite LVAD bridging; leaves open optimal timing and adjunctive strategies for this rare disease.
Idiopathic giant cell myocarditis (GCM) is a rare and rapidly progressing form of myocarditis predominantly affecting younger people. We report a case of a 23-year-old athletic patient who presented with features of acute heart failure due to GCM and discuss his management that included a left ventricular assist device as a bridge to transplant. He died immediately following the transplant.We also review the literature on this rare disease, highlighting the advances in the management of the disease including immunosuppressive therapy, ventricular assist devices and heart transplantation.
No takes yet. Share an insight, caveat, or question.
Kasouridis et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: